Evidence map›Paper›PMID 20736987›Full record

Trial reportKidney international2010

Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.

John C Lieske, William J Tremaine, Claudio De Simone, Helen M O'Connor, Xujian Li, Eric J Bergstralh, David S Goldfarb

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Kidney international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00587041 (Use of Oral Probiotics to Reduce Urinary Oxalate Excretion), which is not on this map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00587041 phase1 / phase2completednot on this map

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

TypeinterventionalSponsorMayo ClinicRan2006 to 2009Enrolled40ConditionsNephrolithiasis, Hyperoxaluria, Crohn's DiseaseArmsOxadrop, Agri-King Synbiotic (AKSB), Placebo
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Microbiota and kidney disease: the road ahead.Nature reviews. Nephrology · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Oxalate homeostasis.Nature reviews. Nephrology · 2023
    Review
  14. Review
  15. Article
  16. UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Article
  17. Review
  18. Oxalate nephropathy: a review.Clinical kidney journal · 2022
    Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

John C LieskeDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. Lieske.John@mayo.edu
William J Tremaine
Claudio De Simone
Helen M O'Connor
Xujian Li
Eric J Bergstralh
David S Goldfarb
Mayo Clinic in Florida · USMayo Clinic in Arizona · USUniversity of L'Aquila · ITVA NY Harbor Healthcare System · USWinnMed · US

Funding

Mayo Clinic Urology O'Brien Research CenterP50DK083007 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2008 to 2012
$5.3M
Use of symbiotics to reduce urinary oxalate excretionR21AT002534 · NCCIH · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2005 to 2007
$579k
NCCIH NIH HHS AT R21AT2534NCCIH NIH HHS R21 AT002534NIDDK NIH HHS P50 DK083007NIDDK NIH HHS U54 DK082908
6 · The paper itself

Abstract

We examined the effect of a controlled diet and two probiotic preparations on urinary oxalate excretion, a risk factor for calcium oxalate kidney stone formation, in patients with mild hyperoxaluria. Patients were randomized to a placebo, a probiotic, or a synbiotic preparation. This tested whether these probiotic preparations can increase oxalate metabolism in the intestine and/or decrease oxalate absorption from the gut. Patients were maintained on a controlled diet to remove the confounding variable of differing oxalate intake from food. Urinary oxalate excretion and calcium oxalate supersaturation on the controlled diet were significantly lower compared with baseline on a free-choice diet. Neither study preparation reduced urinary oxalate excretion nor calcium oxalate supersaturation. Fecal lactobacilli colony counts increased on both preparations, whereas enterococcal and yeast colony counts were increased on the synbiotic. Total urine volume and the excretion of oxalate and calcium were all strong independent determinants of urinary calcium oxalate supersaturation. Hence, dietary oxalate restriction reduced urinary oxalate excretion, but the tested probiotics did not influence urinary oxalate levels in patients on a restricted oxalate diet. However, this study suggests that dietary oxalate restriction is useful for kidney stone prevention.

Indexed as

DietAdministration, OralAdultAgedBiomarkersCalcium OxalateDouble-Blind MethodFecesFemaleGastrointestinal TractHumansHyperoxaluriaKidney CalculiLinear ModelsMaleMiddle AgedBiomarkersCalcium Oxalate

Identifiers

PMID20736987
PMCPMC3923490
OpenAlexW2094583201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.